Name: 글로벌 시장 동향
SKU: DMPH26
Availability: InStock

보고서 요약(국문)

시장 개요
쇼그렌 증후군 시장 규모는 2023년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상되며, 예측 기간(2023-2030년) 동안 연평균 4.2%의 성장률을 보일 것으로 전망됩니다.
쇼그렌 증후군(SS)은 면역계 질환으로, 가장 대표적인 두 가지 증상은 안구건조증과 구강건조증입니다. 이 증후군은 루푸스, 류마티스 관절염과 같은 다른 면역계 질환과 동반되는 경우가 흔합니다. 쇼그렌 증후군에서는 일반적으로 입과 눈의 점막 및 수분 분비샘이 먼저 영향을 받아 타액과 눈물 분비가 감소합니다. 이 질환은 여성에게서 훨씬 더 흔하게 발생합니다. 치료의 목표는 증상을 완화하는 것입니다.

시장 동향
전 세계 쇼그렌 증후군 시장 성장을 이끄는 주요 요인은 쇼그렌 증후군 및 기타 자가면역 질환의 발생률 증가, 질환에 대한 인식 제고 및 최첨단 의료 서비스에 대한 수요 증가, 그리고 탄탄한 신약 파이프라인입니다.
쇼그렌 증후군 및 기타 자가면역 질환의 발생률 증가는 시장 성장을 견인할 것으로 예상됩니다.
쇼그렌 증후군(SS)의 주요 증상은 구강 건조와 안구 건조입니다. 이 질환은 어느 연령에서든 발생할 수 있지만, 중년 이후에 점진적으로 악화되는 경우가 많습니다. 쇼그렌 증후군은 면역 체계가 신체의 조직과 장기를 공격하는 자가면역 질환의 한 종류입니다. 쇼그렌 증후군에서는 면역 체계가 주로 침샘과 눈물샘을 공격하여 눈물과 타액 분비 기능을 저하시킵니다. 쇼그렌 증후군의 발병률은 류마티스 관절염(RA)의 절반 수준으로, 인구의 0.5%~1.0%에 영향을 미칩니다.
미국 국립생명공학정보센터(NCBI, 2022)에 따르면, 쇼그렌 증후군은 성인 40만 명에서 310만 명에게 영향을 미칩니다. 이 질환은 모든 연령대에서 발생할 수 있지만, 평균 발병 연령은 45세에서 55세 사이입니다. 쇼그렌 증후군 환자의 약 절반에서는 류마티스 관절염 및 루푸스와 같은 다른 결합 조직 질환이 동반됩니다.
쇼그렌 증후군은 전 세계적으로 성인과 소아에서 드물게 발생하며, 인종이나 지역에 따른 발병률 차이는 없는 것으로 보입니다. 그러나 이 질환은 여성에게서 더 흔하게 발생하며, 전신성 홍반성 루푸스(SLE)와 유사하게 여성 대 남성 비율은 약 9:1입니다. 쇼그렌 증후군은 일반적으로 중년기에 발병하지만, 어린아이와 노인에게도 발생할 수 있습니다.

쇼그렌 증후군 치료제의 가용성에 대한 정보 부족은 시장 성장을 저해할 것으로 예상됩니다.
또한, 높은 치료 비용과 쇼그렌 증후군의 후유증(급성 탈수, 급격한 체중 감소, 염증 등)은 시장 확대를 제약할 것입니다. 앞서 언급한 예측 기간 동안 쇼그렌 증후군 시장은 질환, 예방 조치 및 약물 부작용에 대한 정보 부족으로 어려움을 겪을 것입니다.
코로나19 영향 분석
팬데믹 기간 동안 대부분의 산업은 부정적인 영향을 받았습니다. 이는 다양한 예방적 봉쇄 조치와 국제 규제 기관에서 부과한 기타 제한으로 인해 제조 및 공급망에 상당한 차질이 발생했기 때문입니다. 시장도 마찬가지입니다. 대다수 사람들의 전반적인 경제 상황은 팬데믹으로 인해 심각한 타격을 입었고, 사람들은 불필요한 지출을 줄이려는 경향이 강해지면서 소비 수요가 감소했습니다. 예측 기간 동안 이러한 요인들이 시장에 부정적인 영향을 미칠 것으로 예상됩니다.

다양한 공급망의 회복력을 강화하여 필수 원자재에 대한 안정적인 접근성을 확보하는 데 대한 관심이 다시 높아지고 있습니다. 새로운 코로나19 백신과 치료제 승인의 시급성으로 인해 규제 기관은 평가 및 승인 절차를 간소화했습니다. 이러한 발전이 향후 의약품의 임상적 및 상업적 성공을 높일 것으로 기대됩니다. 그러나 전 세계 쇼그렌 증후군(SS) 산업은 관련 정부 당국이 봉쇄 조치를 해제하기 시작하면 회복될 것으로 예상됩니다.
세그먼트 분석
병원 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
쇼그렌 증후군 환자의 입원율은 일반 인구보다 높았습니다. 쇼그렌 증후군 환자는 대조군에 비해 내분비/대사 질환, 심혈관 질환, 근골격계 질환, 결합 조직 질환 및 외상으로 입원할 가능성이 더 높았습니다. 2022년 10월 쇼그렌 증후군 뉴스에 따르면, 쇼그렌 증후군 환자는 지역사회에서 감염되는 질환, 특히 폐와 장 감염으로 인해 입원 치료가 필요한 경우가 더 많습니다. 결핵균 감염이나 수두/대상포진 바이러스(조스터) 감염과 같은 기회 감염으로 인한 입원 또한 이 환자군에서 더 흔합니다. 쇼그렌 증후군 환자의 첫 감염으로 인한 전체 입원율은 건강한 사람보다 98% 더 높았습니다.
프랑스 몽펠리에 대학의 전문가들에 따르면, 다른 자가면역 질환과 관련된 감염의 영향은 광범위하게 논의되어 왔지만, 쇼그렌 증후군 환자에서 입원이 필요한 중증 감염의 유병률에 대해서는 알려진 바가 거의 없습니다.
지리적 분석
북미는 전 세계 쇼그렌 증후군 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미가 전 세계 쇼그렌 증후군 시장을 주도하는 주된 이유는 방대한 인구, 우수한 의료 인프라, 그리고 높은 소득 수준 때문입니다. 존스 홉킨스 쇼그렌 증후군 센터(2021년)에 따르면 미국인 200명 중 약 1명이 쇼그렌 증후군의 영향을 받는 것으로 추정됩니다. 쇼그렌 증후군이 의심되는 환자는 전문 의료진의 평가를 받아야 합니다. 존스 홉킨스 제롬 그린 쇼그렌 증후군 센터의 의료진은 쇼그렌 증후군의 진단, 치료 및 연구 분야에서 풍부한 경험을 보유하고 있습니다. 이들의 전문 지식은 현재 메릴랜드주 볼티모어에 있는 존스 홉킨스 베이뷰 캠퍼스 내 접근성이 좋은 시설에 집중되어 있습니다. 류마티스내과, 안과, 신경과, 산부인과 전문의로 구성된 이 팀은 매년 쇼그렌 증후군이 의심되거나 확진된 200~300명의 신규 환자를 진료합니다.
또한, 이 지역에는 많은 기업들이 있으며, 쇼그렌 증후군 관련 산업이 지역 경제를 활성화시키고 있습니다. 예를 들어, 2022년 9월에는 노바티스가 쇼그렌 증후군 2상 임상시험을 완료함에 따라 향후 전망이 밝아졌습니다. Clinical Trials Arena 팀은 또한 리슈마니아증 임상시험 중단, 림프종 임상시험 종료, 자궁내막증 및 안구건조증 임상시험 완료 소식도 주목하고 있습니다. 노바티스의 레미브루티닙(LOU-064)은 2상 임상시험 완료 후 쇼그렌 증후군 치료제로서 임상 전환 성공률(PTSR)이 8%포인트 상승한 34%를 기록했습니다.
경쟁 환경
쇼그렌 증후군 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 기업으로는 노바티스, 알러간, 오츠카제약, 산텐제약, 니콕스, 아르젠티스, 오벤테라퓨틱스, 애브비, 셀좀, 바이오젠 등이 있습니다. 주요 업체들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 채택하여 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 11월, 모토헬스(Motto Health)는 쇼그렌 증후군을 포함한 자가면역 질환 및 만성 염증성 질환 환자를 위해 류마티스 전문의 및 의료 전문가가 참여하는 가상 클리닉을 개설했다고 스타트업 측이 밝혔습니다. 이 기술을 통해 환자들은 온라인 애플리케이션을 사용하여 증상을 관리 및 추적하고, 의사와의 가상 상담을 예약하고, 맞춤형 치료 계획을 받을 수 있습니다.
노바티스(Novartis AG)

개요: 노바티스(Novartis AG)는 전문의약품 및 일반의약품, 안과 제품의 개발, 생산 및 마케팅을 전문으로 하는 헬스케어 기업입니다. 감염, 암, 심혈관 질환, 피부 질환, 신경 질환, 안과 및 호흡기 질환 치료제를 제공하며, 자회사인 산도즈(Sandoz)를 통해 바이오시밀러 및 제네릭 의약품을 공급합니다. 노바티스는 노바티스 생물의학 연구소(Novartis Institutes for BioMedical Research, NIBR)를 통해 다양한 질병 분야에서 연구를 수행하고 있습니다.
제품 포트폴리오:
히드록시클로로퀸(플라케닐): 항류마티스제인 히드록시클로로퀸(플라케닐)은 질병 조절 항류마티스제(DMARD)입니다. 관절염 통증과 부기를 완화하고, 관절 퇴행을 멈추고 영구적인 장애 발생 가능성을 줄일 수 있습니다. 히드록시클로로퀸은 원래 말라리아 치료 및 예방에 사용되었던 약물 계열에 속합니다.
주요 개발 사항: 2022년 9월, 노바티스는 쇼그렌 증후군 2상 임상시험을 완료했습니다. 이후 내장형 리슈마니아증 1상 임상시험을 중단하고, B세포 림프종 1상 임상시험을 종료했으며, 자궁내막증 및 안구건조증 1상 임상시험을 완료했습니다.

글로벌 쇼그렌 증후군 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
Sjögren’s Syndrome Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).
The two most typical symptoms of Sjogren's syndrome (SS), an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. The mucosal membranes and moisture-secreting glands of the mouth and eyes are typically impacted first in Sjogren's syndrome, which causes less saliva and tears to be produced. In women, the illness is far more prevalent. The goal of treatment is to diminish symptoms.
Market Dynamics
The major factors driving the global sjogren’s syndrome market are that Sjogren’s syndrome and other autoimmune illnesses are becoming more common, increasing awareness and the need for cutting-edge medical care, additionally, a strong drug pipeline has contributed to the market's expansion
Sjogren's syndrome and other autoimmune illnesses are becoming more common and are expected to drive the market’s growth.
The primary symptoms of Sjogren syndrome (SS) are dry mouth and eyes. The illness can happen at any age, but it often starts to worsen progressively in middle adulthood. Sjogren syndrome is one of a vast set of ailments known as autoimmune disorders that take place when the immune system targets the body's own tissues and organs. In Sjogren syndrome, the immune system predominantly targets the salivary glands and the lacrimal glands, which limit the glands' capacity to secrete tears and saliva. The incidence of Sjogren syndrome is close to half that of rheumatoid arthritis (RA), or it affects 0.5% to 1.0% of the population, according to
The National Centre for Biotechnology Information 2022. Sjogren’s syndrome affects between 400,000 and 3.1 million adult people. Although this illness can affect individuals of any age, the average onset of symptoms is between the ages of 45 and 55. Rheumatoid arthritis and other connective tissue illnesses, such lupus, are also present in about half of patients.
Sjogren has been recorded in adults and children less frequently throughout the world, and there doesn't seem to be any racial or geographic bias in incidence. However, the disorder has a clear preference for females, and similar to SLE, the female: male ratio is around 9:1. The condition typically manifests in middle age, but it can also affect young children and the elderly.
Lack of knowledge regarding the availability of the Sjogren's syndrome drug is expected to hamper the market’s growth.
However, the high cost of treatment and sjogren's disease consequences such acute dehydration, rapid weight loss, and inflammation will restrain market expansion. During the aforementioned projection period, the sjogren’s syndrome market will face challenges from a lack of knowledge regarding the condition, its preventative measures, and drug side effects.
COVID-19 Impact Analysis
During the Pandamic, most industries experienced negative repercussions. This can be attributed to significant disruptions in their manufacturing and supply chains as a result of various preventative lockdowns and other limitations imposed by international regulatory organizations. The market is the same. The general economic status of the majority of people has been severely hit by the pandamic, which has also resulted in a fall in consumer demand as people are more inclined to eliminate non-essential expenditure from their budgets. During the projected period, it is anticipated that the aforementioned factors will have a negative impact on the market.
There is also a resurgence of interest in enhancing the resilience of diversified supply chains to provide reliable access to vital raw materials. Due to the urgent need to approve new COVID-19 vaccines and therapies, regulatory agencies have simplified the evaluation and approval processes. It is hoped that these advancements will increase the clinical and commercial success of future medicines. However, it is projected that the worldwide Sjogren syndrome (SS) industry will recover once the relevant governing authorities start pharmaceuticals lift such imposed lockdowns.
Segment Analysis
The hospital’s segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Hospitalization rates were greater for SS patients than for the general population. Patients with SS were more likely than comparators to be hospitalized for endocrine/metabolic illnesses, cardiovascular diseases, musculoskeletal diseases, connective tissue disorders, and traumas. People with Sjogren's disease are more likely to need inpatient hospital care for infections picked up in the community, especially those of the lungs and intestines, according to Sjogren’s syndrome News from October 2022. Hospitalizations for opportunistic infections, such as mycobacterium infections and the chickenpox/shingles virus (zoster), are also more common in this patient population. Sjogren's patients had a 98% higher overall hospitalization rate for a first infection than healthy individuals did.
According to experts from the University of Montpellier in France, while the effect of infections on outcomes related to other autoimmune illnesses has been extensively discussed, little is known regarding the prevalence of severe infections necessitating hospitalization in Sjogren's patients.
Geographical Analysis
North America holds the largest market share in the global Sjogren’s Syndrome market.
North America dominates the global Sjogren’s syndrome market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 1 in 200 Americans are thought to be affected by Sjogren’s syndrome, according to the Johns Hopkins Sjogren's Center 2021. A team of knowledgeable professionals must evaluate patients who believe they may have Sjogren’s syndrome. The doctors at the Jerome Greene Sjogren’s syndrome Center at Johns Hopkins have great experience in Sjogren’s syndrome diagnosis, treatment, and research. Their knowledge is currently centralized in a facility easily accessible on the Johns Hopkins Bayview campus in Baltimore, Maryland. Rheumatologists, ophthalmologists, neurologists, and gynecologists make up the company team and review 200–300 new patients with a suspected or confirmed diagnosis of Sjogren’s syndrome each year.
Additionally, many businesses are there, and the syndrome that propels the region is developing. For instance, in September 20222, advancement prospects increase once Novartis completes a Phase II Sjogren’s syndrome trial. The team at Clinical Trials Arena also looks at a leishmaniasis trial suspension, a lymphoma trial termination, and trial completions for endometriosis and dry eye syndrome. Remibrutinib (LOU-064) from Novartis saw an increase in its Phase Transition Success Rate (PTSR) of eight points to 34% in Sjogren’s syndrome following the conclusion of Phase II research.
Competitive Landscape
The sjogren’s syndrome market is moderately competitive with local and global companies’ presence. Novartis AG, Allergan Inc, Otsuka Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd., Nicox S.A, Argentis Pharmaceuticals, LLC, Auven Therapeutics, Abbvie Inc Cellzome GmbH, Biogen Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in November 2022, For those with autoimmune and chronic inflammatory disorders, including Sjogren’s syndrome, Motto Health has opened a kind of virtual clinic with rheumatologists and medical specialists, the startup revealed. The technology enables patients to manage and track symptoms, schedule virtual consultations with physicians, and obtain individualized treatment regimens using an online application.
Novartis AG.
Overview: A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. Among other things, it offers medicines for the treatment of infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis carries out research in a number of illness areas (NIBR).
Product Portfolio:
Hydroxychloroquine (Plaquenil): The anti-rheumatic medicine hydroxychloroquine (Plaquenil) is a disease-modifying medication (DMARD). It can lessen arthritic pain and swelling. It might stop joint deterioration and lessen the possibility of permanent impairment. The drug hydroxychloroquine belongs to a group of drugs that were initially used to treat and prevent malaria.
Key Development: In September 2022, Sjogren’s syndrome Phase II trial by Novartis is now complete. After that, they suspend the Phase I study for visceral leishmaniasis, end the Phase I trial for B-cell lymphoma, and complete the Phase I trials for endometriosis and dry eye syndrome.
The global Sjogren’s Syndrome market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Sjogren's syndrome and other autoimmune illnesses are becoming more common
4.1.1.2. Increasing awareness and the need for cutting-edge medical care
4.1.2. Restraints:
4.1.2.1. Lack of knowledge regarding the availability of the Sjogren's syndrome drug
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Cholinergic Agonists
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Off-Label Drugs
8. By Symptoms
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
8.1.2. Market Attractiveness Index, By Symptoms
8.2. Dry eyes
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Dry mouth
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Primary Sjogren’s Syndrome
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Secondary Sjogren’s Syndrome
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacy
10.4. Online Pharmacy
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Allergan Inc
13.3. Otsuka Pharmaceutical Co., Ltd
13.4. Santen Pharmaceutical Co., Ltd.
13.5. Nicox S.A
13.6. Argentis Pharmaceuticals, LLC
13.7. Auven Therapeutics
13.8. Abbvie Inc
13.9. Cellzome GmbH.
13.10. Biogen In.
LIST NOT EXHAUSTIVE
14. Global Sjogren’s Syndrome Market – DataM
14.1. Appendix
14.2. About Us and Application
14.3. Contact Us

언급된 주요 기업들

Novartis AG, Allergan Inc, Otsuka Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd., Nicox S.A, Argentis Pharmaceuticals, LLC, Auven Therapeutics, Abbvie Inc, Cellzome GmbH., Biogen In.

표 목록 (Tables)

List of Tables

Table 1 Global Sjogren's Disease Market Value, By Type, 2025, 2029 & 2033 (US$ Million)

Table 2 Global Sjogren's Disease Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 3 Global Sjogren's Disease Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 4 Global Sjogren's Disease Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 5 Global Sjogren's Disease Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 6 Global Sjogren's Disease Market Value, By Type, 2025, 2029 & 2033 (US$ Million)

Table 7 Global Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 8 Global Sjogren's Disease Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 9 Global Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 10 Global Sjogren's Disease Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 11 Global Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 12 Global Sjogren's Disease Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 13 Global Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 14 Global Sjogren's Disease Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 15 Global Sjogren's Disease Market Value, By Region, 2022-2033 (US$ Million)

Table 16 North America Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 17 North America Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 18 North America Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 19 North America Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 20 North America Sjogren's Disease Market Value, By Country, 2022-2033 (US$ Million)

Table 21 Europe Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 22 Europe Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 23 Europe Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 24 Europe Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 25 Europe Sjogren's Disease Market Value, By Country, 2022-2033 (US$ Million)

Table 26 Asia-Pacific Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 27 Asia-Pacific Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 28 Asia-Pacific Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 29 Asia-Pacific Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 30 Asia-Pacific Sjogren's Disease Market Value, By Country, 2022-2033 (US$ Million)

Table 31 South America Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 32 South America Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 33 South America Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 34 South America Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 35 South America Sjogren's Disease Market Value, By Country, 2022-2033 (US$ Million)

Table 36 Middle East and Africa Sjogren's Disease Market Value, By Type, 2022-2033 (US$ Million)

Table 37 Middle East and Africa Sjogren's Disease Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 38 Middle East and Africa Sjogren's Disease Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 39 Middle East and Africa Sjogren's Disease Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 40 Middle East and Africa Sjogren's Disease Market Value, By Country, 2022-2033 (US$ Million)

Table 41 Amgen: Overview

Table 42 Amgen: Product Portfolio

Table 43 Amgen: Key Developments

Table 44 F. Hoffmann-La Roche Ltd.: Overview

Table 45 F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 46 F. Hoffmann-La Roche Ltd.: Key Developments

Table 47 Pfizer Inc.: Overview

Table 48 Pfizer Inc.: Product Portfolio

Table 49 Pfizer Inc.: Key Developments

Table 50 Haleon Group of Companies: Overview

Table 51 Haleon Group of Companies: Product Portfolio

Table 52 Haleon Group of Companies: Key Developments

Table 53 AstraZeneca: Overview

Table 54 AstraZeneca: Product Portfolio

Table 55 AstraZeneca: Key Developments

Table 56 Sanofi SA: Overview

Table 57 Sanofi SA: Product Portfolio

Table 58 Sanofi SA: Key Developments

Table 59 Bristol-Myers Squibb Company: Overview

Table 60 Bristol-Myers Squibb Company: Product Portfolio

Table 61 Bristol-Myers Squibb Company: Key Developments

Table 62 Teva Pharmaceutical Industries Ltd.: Overview

Table 63 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 64 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 65 Horizon Therapeutics plc: Overview

Table 66 Horizon Therapeutics plc: Product Portfolio

Table 67 Horizon Therapeutics plc: Key Developments

Table 68 Bausch Health Companies Inc.: Overview

Table 69 Bausch Health Companies Inc.: Product Portfolio

Table 70 Bausch Health Companies Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 2 Global Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 5 Global Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 6 Global Sjogren's Disease Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Sjogren's Disease Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 8 Primary Sjogren's Syndrome Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 9 Secondary Sjogren's Syndrome Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 10 Global Sjogren's Disease Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 11 Corticosteroids Drug Class in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 12 Nonsteroidal Anti-Inflammatory Drugs Drug Class in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 13 Immunosuppressants Drug Class in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 14 Biologics Drug Class in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 15 Other Drug Classes in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 16 Global Sjogren's Disease Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 17 Oral Route of Administration in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 18 Injectable Route of Administration in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 19 Topical Route of Administration in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 20 Global Sjogren's Disease Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 23 Online Pharmacies Distribution Channel in Global Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 24 Global Sjogren's Disease Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 25 North America Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 26 North America Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 27 North America Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 28 North America Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 29 North America Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 30 North America Sjogren's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 32 Europe Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 33 Europe Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 34 Europe Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 35 Europe Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 Europe Sjogren's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 37 Asia-Pacific Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 38 Asia-Pacific Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 39 Asia-Pacific Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 40 Asia-Pacific Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 41 Asia-Pacific Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Asia-Pacific Sjogren's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 43 South America Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 44 South America Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 45 South America Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 46 South America Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 47 South America Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 48 South America Sjogren's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 49 Middle East and Africa Sjogren's Disease Market Value, 2022-2033 (US$ Million)

Figure 50 Middle East and Africa Sjogren's Disease Market Share, By Type, 2024 & 2033 (%)

Figure 51 Middle East and Africa Sjogren's Disease Market Share, By Drug Class, 2024 & 2033 (%)

Figure 52 Middle East and Africa Sjogren's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 53 Middle East and Africa Sjogren's Disease Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 54 Amgen: Financials

Figure 55 F. Hoffmann-La Roche Ltd.: Financials

Figure 56 Pfizer Inc.: Financials

Figure 57 Haleon Group of Companies: Financials

Figure 58 AstraZeneca: Financials

Figure 59 Sanofi SA: Financials

Figure 60 Bristol-Myers Squibb Company: Financials

Figure 61: Teva Pharmaceutical Industries Ltd.: Financials

Figure 62 Horizon Therapeutics plc: Financials

Figure 63 Bausch Health Companies Inc.: Financials

세계의 쇼그렌 증후군 시장(2023-2030년)

Global Sjogren’s Syndrome Market - 2023-2030